Blog
FDA Approves Giredestrant (Wilserdly): A New All-Oral Option When Breast Cancer Outsmarts Hormone Therapy
On November 16, 2026, the FDA approved giredestrant (Wilserdly) plus everolimus for ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation. In the evERA trial, the all-oral combination kept cancer from progressing for a median of 10.0 months versus 5.5. Here is who it helps, how the blood test works, and the side effects worth planning for.